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In established acute kidney injury (AKI), serum creatinine
poorly differentiates prerenal from intrinsic AKI. In this study,
we tested whether urinary neutrophil gelatinase-associated
lipocalin (NGAL) distinguishes between intrinsic and prerenal
AKI, and tested its performance in predicting a composite
outcome that included progression to a higher RIFLE (Risk,
Injury, Failure, Loss of function, End stage renal disease) class,
dialysis, or death. Urinary NGAL was measured using a
standardized clinical platform in 161 hospitalized patients
with established AKI. Sixteen patients were excluded because
of postrenal obstruction or insufficient clinical information.
Of the remaining 145 patients, 75 had intrinsic AKI, 32 had
prerenal AKI, and 38 patients could not be classified. Urinary
NGAL levels effectively discriminated between intrinsic and
prerenal AKI (area under the receiver-operating characteristic
curve 0.87). An NGAL level over 104lg/l indicated intrinsic
AKI (likelihood ratio 5.97), whereas an NGAL level o47lg/l
made intrinsic AKI unlikely (likelihood ratio 0.2). Patients
experiencing the composite outcome had significantly higher
median urinary NGAL levels on inclusion. In logistic regression
analysis, NGAL independently predicted the composite
outcome when corrected for demographics, comorbidities,
creatinine, and RIFLE class. Hence, urinary NGAL is useful
in classifying and stratifying patients with established AKI.
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Acute kidney injury (AKI) is common in hospitalized
patients and is increasing in incidence.1,2 Both the ‘Risk,
Injury, Failure, Loss of function, End stage renal disease’
(RIFLE) classification from the acute dialysis quality
initiative and the acute kidney injury network (AKIN)
definition of AKI are based on serum creatinine levels and
urinary output to define the severity of AKI.3,4 Both
classifications are effective in risk stratifying patients, as
the more advanced RIFLE or AKIN stages predict poor
clinical outcomes. However, serum creatinine levels do not
always reflect the severity of renal damage. First, during early
AKI even a large decrease in glomerular filtration rate may
cause only a modest increase in serum creatinine, because
creatinine must first accumulate in the blood. Second,
underlying chronic kidney disease (CKD) can cause a high
serum creatinine level in the absence of AKI. Missing
information about the baseline creatinine level often
confounds interpretation of an elevated serum creatinine
concentration. Third, substantial increases in serum creati-
nine can be observed in renal hypoperfusion even when the
kidneys are structurally intact, resulting in prerenal AKI.5
Patients with prerenal and postrenal AKI must be identified
as soon as possible, as their treatment is decidedly different
than that of patients with intrinsic AKI.5,6 Importantly,
prerenal AKI is associated with a lower mortality than
intrinsic AKI.2 Serum and urine diagnostic indices, including
fractional excretion of sodium (FeNa), fractional excretion of
urea (FeUrea), and urea creatinine (UC) ratio are commonly
determined; however, these indices may be of limited utility
in diagnosing intrinsic AKI.5,7–9 Hence, the diagnostic
workup and therapeutic management of patients with
established AKI would greatly benefit from a clinical test
that facilitates a differential diagnosis of intrinsic and
prerenal AKI at an early time point and that helps in
stratifying the patient at risk.
Novel biomarkers of renal tubular damage potentially
fulfill the criteria of such a test. They include (but are not
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limited to) neutrophil gelatinase-associated lipocalin
(NGAL), kidney injury molecule-1, liver-type fatty acid-
binding protein, and interleukin 18.10 These molecules are
produced within the kidney in response to injury and can be
detected in plasma or urine. In contrast to conventional
markers, such as serum creatinine, blood urea nitrogen, or
serum cystatin C, these markers do not reflect kidney
function, but instead signify structural damage to cells of
the kidney. Consequently, these markers are rapidly detect-
able in response to injury and their increased levels are
independent of a functional deficit. Conversely, a purely
functional drop of glomerular filtration rate, as is the case in
pure prerenal AKI, is not expected to result in an
upregulation of these markers. Hence, the detection of novel
biomarkers in the setting of established AKI (by creatinine
criteria) may facilitate a differential diagnosis between
prerenal and intrinsic AKI and aid in risk-stratifying patients
beyond currently available parameters (for example, creati-
nine or RIFLE class).
One of the most promising novel biomarkers is NGAL, a
25 kDa protein that is produced in renal tubules in response
to structural kidney injury11,12 and secreted into the urine.13
In previous studies, NGAL was effective in the early diagnosis
of AKI in several clinical settings, including perioperative
AKI, contrast-induced AKI, sepsis-associated AKI, and AKI
following kidney transplantation.14–19 Importantly, NGAL
effectively discriminated patients in the emergency room
with intrinsic AKI from those with other diagnoses including
prerenal AKI, CKD, and those who actually had normal renal
function.20 Furthermore, several studies suggested that
NGAL could be useful in the prediction of poor clinical
outcomes in AKI.17,20–22 In this study, we addressed the
performance of urinary NGAL levels in established AKI based
on RIFLE criteria. Specifically, we asked whether NGAL
would aid in distinguishing intrinsic from prerenal causes
and predict an unfavorable clinical course.
RESULTS
Patient characteristics
Of 161 patients initially included into the study for
established AKI (RIFLE-R, -I, or -F) 16 were excluded for
postrenal obstruction (n¼ 6) or insufficient clinical informa-
tion (n¼ 10). The remaining 145 patients were included into
the outcome analysis and underwent diagnostic adjudication
(Figure 1). At the time of inclusion into the study, 32 patients
(22.1%) had RIFLE-R AKI, 65 (44.8%) had RIFLE-I AKI, and
48 (33.1%) had RIFLE-F AKI. In all, 49 patients (33.8%)
experienced the composite outcome. Of these, 19 patients
(13.1%) displayed a step-up in RIFLE severity class, 18
patients (12.4%) required renal replacement therapy, and 28
patients (19.3%) died.
Patients who experienced the composite outcome did not
differ significantly from all other patients with respect to
demographics or comorbidities, although a previous history
of CKD (stage 3 or up) tended to be more frequent in
patients with an unfavorable clinical course (P¼ 0.097;
Table 1). Serum creatinine and blood urea nitrogen levels at
the time of inclusion were significantly higher in patients
who experienced the composite outcome compared with all
others, whereas RIFLE class, UC ratio, FeNa, and FeUrea were
not significantly different.
A total of 107 patients were ultimately diagnosed with
prerenal AKI (n¼ 32) or intrinsic AKI (n¼ 75). Of patients
with intrinsic AKI, 46 patients (61.3%) had a clinical
diagnosis of acute tubular necrosis, whereas 29 patients
(38.7%) had intrinsic AKI caused by other renal diseases,
mainly nephrotoxic AKI (n¼ 9) and acute glomerulone-
phritis (n¼ 7). In all, 38 patients were unclassifiable, because
they could not be clearly attributed to one of the two
categories even after thorough inspection of all clinical
information. In most of these cases, we could not
differentiate prerenal AKI from acute tubular necrosis based
on the clinical information (n¼ 24). In other cases, a
prerenal event coincided with contrast agent administra-
tion (n¼ 10) or other potential nephron-damaging events
(n¼ 4).
Patients with prerenal AKI were significantly older than
patients with intrinsic AKI (Table 1). In addition, congestive
heart failure was significantly more frequent in patients with
prerenal AKI. Serum creatinine and RIFLE severity class on
inclusion were significantly higher in patients with intrinsic
AKI when compared with prerenal AKI. The composite
outcome (step-up in RIFLE severity class, dialysis initiation,
or mortality) was experienced by 38 patients with intrinsic
AKI (50.7%), but only by 2 patients with prerenal AKI (6.3%,
Po0.001; Table 1). Of these two patients with prerenal AKI
and adverse outcomes, one received a single session of
hemodialysis in the setting of diuretics-induced prerenal AKI
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Figure 1 | Study flow diagram. AKI, acute kidney injury.
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in chronic congestive heart failure, but made a quick recovery
of creatinine thereafter. The other patient had diarrhea-
induced prerenal AKI and initially recovered from AKI, but
died later during hospitalization from an unrelated event.
Unclassifiable cases resembled prerenal AKI cases with respect
to demographics and comorbidities, but displayed higher
peak creatinine levels during follow-up and more unfavorable
clinical outcomes, which reflects the fact that they represent
neither purely prerenal nor purely intrinsic AKI by clinical
criteria (Table 1).
Table 1 | Patient characteristics by clinical course and diagnosis
Clinical course after inclusion Diagnosis on inclusion
Characteristic
All patients
(n=145)
Composite outcome
(n=49)
No aspect of
composite outcome
(n=94)
Intrinsic AKI
(n=75)
Prerenal AKI
(n=32)
Unclassifiable
(n=38)
Demographics
Mean age (s.d.), years 67.7 (14.4) 65.6 (14.4) 68.8 (14.4) 64.3 (15.5)y 71.1 (14.2) 71.5 (10.7)
Women, n (%) 59 (40.7) 19 (38.8) 40 (41.7) 27 (36.0) 14 (43.8) 18 (47.4)
Black race, n (%) 1 (0.7) 0 (0) 1 (1) 0 (0) 1 (3.1) 0 (0)
Comorbidities
Congestive heart failure, n (%) 101 (69.7) 34 (69.4) 67 (69.8) 42 (56.0)y 26 (81.3) 33 (86.8)
Diabetes mellitus, n (%) 42 (29) 12 (24.5) 30 (31.3) 19 (25.3) 11 (34.4) 12 (31.6)
Hypertension, n (%) 118 (81.4) 40 (81.6) 78 (81.3) 54 (72.0) 28 (87.5) 36 (94.7)
Coronary artery disease, n (%) 44 (30.3) 17 (34.7) 27 (28.1) 18 (24.0) 11 (34.4) 15 (39.5)
Peripheral artery disease, n (%) 21 (14.5) 9 (18.4) 12 (12.5) 10 (13.3) 6 (18.8) 5 (13.2)
Cerebrovascular disease, n (%) 13 (9) 4 (8.2) 9 (9.4) 7 (9.3) 2 (6.3) 4 (10.5)
CKD stage at baseline (based
on eGFR), n (%)a
Stage 1: X90 43 (29.7) 13 (26.5) 30 (31.3) 28 (37.3) 7 (21.9) 8 (21.1)
Stage 2: 60–89 64 (44.1) 19 (38.8) 45 (46.9) 28 (37.3) 11 (34.4) 25 (65.8)
Stage 3: 30–59 33 (22.8) 15 (30.6) 18 (18.8) 14 (18.7)yy 14 (43.8) 5 (13.2)
Stage 4: 15–29 5 (3.4) 2 (4.1) 3 (3.1) 5 (6.7) 0 (0) 0 (0)
CKD stage 3 or up at baseline, n (%) 38 (26.2) 17 (34.7) 21 (21.9) 19 (25.3) 14 (43.8) 5 (13.2)
Kidney parameters on inclusionb
Median serum creatinine baseline,
mmol/l (IQR)
87 (69–105.5) 89 (68.5–121.5) 84.5 (69.3–100) 83 (69–108) 95.5 (77–115.5) 79 (66.8–95)
Median serum creatinine on inclusion,
mmol/l (IQR)
202 (157.5–263.5) 225 (170–299)* 188.5 (154.3–245.5) 233 (190–357)yyy 175.5 (141.3–223) 168 (151.8–220.3)
Median serum creatinine
inclusion/baseline, ratio (IQR)
2.3 (1.8–3.3) 2.4 (1.9–3.4) 2.2 (1.8–3.1) 2.9 (2.1–3.8)yyy 2 (1.7–2.4) 2 (1.7–2.7)
Median serum urea/serum creatinine
ratio (IQR)
81.9 (57.2–100.4) 87.8 (57.4–102.2) 81.2 (56.3–100) 70 (47.6–91) 95.5 (68.8–122.7) 89.5 (75.4–107.5)
Median fractional excretion of
sodium, % (IQR)
0.9 (0.3–2.2) 0.7 (0.2–2.1) 1 (0.3–2.6) 1 (0.4–2.7) 1 (0.3–2.1) 0.6 (0.2–2.2)
Median fractional excretion
of urea, % (IQR)
24.9 (15.4–43.3) 23.9 (12.8–44.5) 25.1 (16.1–41) 33.5 (14.9–49.7) 23.8 (16.3–31.7) 20.3 (13.9–30.6)
Median NGAL on inclusion, mg/l (IQR) 95.4 (37.6–362.2) 248.2 (78–1010.6)*** 68.3 (26.9–214) 255.6 (98.5–872.9)yyy 31.3 (15.9–75.5) 49.3 (29.8–112.1)
Median NGAL on inclusion,
mg/g creatinine (IQR)
115.7 (35.9–370.9) 235.4 (103.8–900.6)** 71.8 (28–220.7) 273.5 (112.9–890.8)yy 36.5 (18.5–75.7) 51.4 (27–166.2)
Development of kidney parameters after inclusion
Median serum creatinine 2 days
after inclusion, mmol/l (IQR)
148 (102–242) 205 (149–366.5)** 121.5 (95–168.5) 199 (139–389)yyy 116.5 (87.5–152.3) 111 (84.3–164.3)
Median peak serum creatinine
within 7 days, mmol/l (IQR)
190 (133.8–300.3) 273 (204.8–436.3)*** 159 (127–233.3) 277 (191–422.8)yyy 128.5 (113.5–162.8) 154 (126.3–227.8)
Median NGAL 2 days after
inclusion, mg/l (IQR)
102.2 (35.1–326.5) 474.2 (119.4–1250.4)*** 64.1 (27.1–139.3) 187.2 (99.1–891.4)y 22.1 (10.2–91.8) 41.2 (28.6–136)
Median NGAL 2 days after inclusion,
mg/g creatinine (IQR)
113.4 (39.2–482.2) 483.1 (113.4–1576.8)** 78.3 (27.9–260.6) 330.4 (103.1–1517.2)y 30.6 (11.4–81.7) 61.3 (32.2–184.4)
Outcomes
Step-up in RIFLE class after inclusion, n (%) 19 (13.4) 14 (19.4)yy 0 (0) 5 (13.2)
Initiation of renal replacement
therapy, n (%)
18 (12.4) 14 (18.7)y 1 (3.1) 3 (7.9)
In-hospital mortality, n (%) 28 (19.3) 23 (30.7)yy 1 (3.1) 4 (10.5)
Composite outcome (unfavorable
clinical course), n (%)
49 (33.8) 38 (50.7)yyy 2 (6.3) 9 (23.7)
Abbreviations: AKI, acute kidney injury; CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; IQR, interquartile range; NGAL, neutrophil gelatinase-
associated lipocalin; RIFLE: Risk, Injury, Failure, Loss of function, End stage renal disease.
aeGFR was calculated using the Modification of Diet in Renal Disease formula.
bUnits for serum creatinine are in mmol/l. To convert serum creatinine from mmol/l to mg/dl, divide by 88.4.
*Po0.05, **Po0.01, ***Po0.001 between patients with and without outcomes using t-test or w2 test as appropriate.
yPo0.05, yyPo0.01, yyyPo0.001 between the intrinsic and prerenal AKI groups using t-test or w2 test as appropriate.
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Urinary NGAL levels in the diagnosis of intrinsic versus
prerenal AKI
NGAL levels were significantly higher in patients with a
clinical diagnosis of intrinsic AKI when compared with
prerenal AKI (P¼ 0.007; Table 1, Figure 2). Unclassifiable
patients displayed intermediate NGAL levels consistent with
the fact that they represent marginal cases. To determine
NGAL test characteristics in the diagnosis of intrinsic AKI
versus prerenal AKI, we performed a receiver-operating
characteristic (ROC) analysis. Table 2 shows the areas under
the ROC curves (AUC-ROC), for different biomarkers of
intrinsic AKI, including NGAL levels, serum creatinine at the
time of inclusion, RIFLE class at the time of inclusion, UC
ratio, FeNa, and FeUrea. The AUC of NGAL (0.87, CI
0.81–0.94) was significantly higher than that of any other
marker tested (Po0.05; Figure 3). We also determined the
sensitivities, specificities, positive and negative predictive
values, and positive and negative likelihood ratios for NGAL
and other biomarkers at different cutoff levels (Table 3). We
had recently conducted a large multicenter study of patients
admitted to emergency rooms, which had indicated that, in
the absence of additional clinical information, a urinary
NGAL level 4104 mg/l was suggestive of intrinsic AKI,
whereas a urinary NGAL level o47 mg/l was suggestive of
normal kidney function, stable CKD, or prerenal AKI.23 To
validate these results in our cohort with established AKI, we
tested these same cutoffs on the current study population. An
NGAL level cutoff level at 104 mg/l provided a high specificity
(0.88) and a high positive likelihood ratio (5.97) for a
diagnosis of intrinsic AKI. This finding indicates that a
urinary NGAL 4104 mg/l in a patient with established AKI is
suggestive of intrinsic AKI. Conversely, an NGAL cutoff level
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Figure 2 |Box plots of biomarker levels in differential diagnosis of acute kidney injury (AKI) and prediction of outcomes. Biomarker
levels are presented on a log 10 scale. Boxes indicate median, lower, and upper quartiles. Lower and upper whiskers represent data
within 1.5 interquartile ranges of the lower quartile and within 1.5 interquartile ranges of the upper quartile, respectively, of log 10-
transformed biomarker levels. Circles represent outliers. NGAL, neutrophil gelatinase-associated lipocalin. *Po0.05, **Po0.01, ***Po0.001.
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of 47 mg/l provided a high sensitivity (0.89) and a negative
likelihood ratio of 0.2 indicating that an NGAL level below
this cutoff is useful in excluding intrinsic AKI. Correction of
the NGAL levels for urinary creatinine yielded similar test
characteristics to NGAL alone (Tables 2 and 3). Test
characteristics of the other markers at percentile-adjusted
cutoffs are shown in Table 3. Together, these data indicate
that NGAL levels can discriminate intrinsic from prerenal
AKI and validate independently derived cutoff levels. Figure 2
shows box plots for urinary NGAL and serum creatinine on
inclusion and 2 days after inclusion, stratified by the
diagnostic category (intrinsic AKI versus prerenal AKI),
demonstrating that NGAL levels displayed less overlap
between the diagnostic groups when compared with serum
creatinine.
NGAL levels in the prediction of an unfavorable clinical
course
To determine the test characteristics of NGAL and other
biomarkers in predicting the composite outcome (step-up in
RIFLE severity class, dialysis initiation, or mortality), we
analyzed biomarker levels, scatter, ROC curves, and per-
formed logistic regression analysis. Median NGAL levels on
inclusion and 2 days after inclusion were significantly higher
in patients, who later experienced the composite clinical
outcome, when compared with all others (Table 1, Figure 2).
We stratified patients into four groups of increasing NGAL
level (o47, 47–104, 104–426, and 4426 mg/l). Cutoffs were
determined based on the 60th, 75th, and 90th percentiles of
NGAL levels in the above-mentioned emergency room
cohort.23 We examined the relationship between the NGAL
level and clinical outcomes (step-up in RIFLE severity
class, dialysis initiation, and mortality). We found a
progressive increase in outcome frequency with increasing
urinary NGAL levels. The associations between NGAL level
and all outcomes (composite and individual AKI outcomes)
were statistically significant (Figure 3). ROC analyses
indicated that NGAL had an AUC-ROC of 0.71 in the
prediction of the composite outcome, whereas serum
creatinine and RIFLE severity class had AUC-ROCs of
0.61 and 0.56, respectively (Table 2).
To analyze the effect of a sustained versus transient
elevation of NGAL on clinical outcomes, we analyzed the
effect of NGAL levels on inclusion in relation to NGAL levels
2 days after inclusion. Within patients with an NGAL level
4104 mg/l on inclusion, 38 patients still displayed an elevated
NGAL 4104 mg/l 2 days after inclusion (sustained elevation
of urinary NGAL), whereas 12 patients had NGAL levels that
normalized to o104 mg/l (transient elevation of urinary
NGAL). Notably, only two patients with a transiently elevated
NGAL excretion (16.7%), but 22 patients with a sustained
elevation of NGAL (57.9%) experienced the composite
outcome indicating an unfavorable clinical course
(Po0.05). These data suggest that a quick normalization of
an elevated NGAL level is predictive of a beneficial outcome,
whereas a sustained high NGAL excretion is a predictor of a
poor clinical course.
We used logistic regression analysis to analyze how urinary
NGAL performed after an adjustment for other clinical
predictors of an unfavorable clinical course or other
established laboratory tests. We generated a conventional
prediction model that corrected for demographics,
Table 2 | ROC analysis of different biomarkers in the
differential diagnosis of AKI and in the prediction of
outcomes
Testa
Diagnosis of
intrinsic AKI
(versus prerenal
AKI)
Prediction of
composite outcome
(unfavorable clinical
course)
Urinary NGAL 0.87 (0.81–0.94)*** 0.71 (0.62–0.8)***
Urinary NGAL/urinary
creatinine
0.89 (0.82–0.95)*** 0.71 (0.62–0.8)***
Serum creatinine 0.74 (0.63–0.84)***,# 0.61 (0.51–0.71)*,y
RIFLE class 0.72 (0.62–0.82)***,# 0.56 (0.47–0.66)#
Fractional excretion of urea 0.59 (0.48–0.71)# 0.49 (0.38–0.6)#
Fractional excretion of
sodium
0.54 (0.42–0.65)# 0.45 (0.34–0.55)#
Serum urea/serum
creatinine ratiob
0.71 (0.59–0.82)**,# 0.48 (0.37–0.58)#
Abbreviations: AKI, acute kidney injury; NGAL, neutrophil gelatinase-associated
lipocalin; RIFLE: Risk, Injury, Failure, Loss of function, End stage renal disease; ROC,
receiver-operating characteristic.
aData represent areas under the ROC curves (AUC-ROC) with 95% confidence
intervals.
bSmaller test result indicates more positive test.
*Po0.05 versus null hypothesis: true area=0.5.
**Po0.01 versus null hypothesis: true area=0.5.
***Po0.001 versus null hypothesis: true area=0.5.
#Po0.05 versus urinary NGAL.
yP=0.067 versus urinary NGAL.
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comorbidities, serum creatinine, and RIFLE class on inclu-
sion and then added NGAL to the model to test whether it
significantly added to the prediction of the composite
outcome (Table 4). We found that age and serum creatinine
were individual parameters that contributed to the prediction
of the composite outcome. NGAL excretion significantly
added to the predictive performance of the model
(Po0.001). Three measures of the overall performance of
the regression model (R square, AUC-ROC, and diagnostic
accuracy) increased when NGAL was added to the model
(Table 4). The adjusted odds ratio of an NGAL 4104 mg/l in
the prediction of the composite outcome was 4.2. These data
indicate that NGAL levels significantly add to the prediction
of an unfavorable clinical course when combined with
conventional predictors.
As these data suggested that urinary NGAL levels may add
to the RIFLE severity classification in risk stratifying patients
with established AKI, we conducted an exploratory analysis
on our data set and stratified patients according to RIFLE
severity class and NGAL level (Figure 4). The analysis
revealed that, within the RIFLE-I class, patients with an
NGAL 4104 mg/l displayed a markedly higher percentage of
poor clinical outcomes, compared with those with an NGAL
p104 mg/l (P¼ 0.001; Figure 4). Within the RIFLE-R or
RIFLE-F class, an NGAL level 4104 mg/l was also associated
with higher percentages of poor clinical outcomes, but these
differences did not reach statistical significance (Figure 4). It
should be noted that our study was originally not powered to
analyze subsets of patients by RIFLE severity class. Yet, these
data strongly suggest that urinary NGAL may be particularly
useful in risk stratifying patients with RIFLE-I AKI.
As urinary NGAL levels diagnosed intrinsic versus
prerenal AKI and were useful in the prediction of an
unfavorable clinical course, we asked in a secondary outcome
analysis whether urinary NGAL may also be useful in
predicting whether established AKI will be transient or
sustained. Therefore we constructed a logistic regression
model that included conventional markers and NGAL in the
prediction of sustained AKI, defined as RIFLE-AKI lasting
more than 3 days. In a conventional prediction model that
was adjusted for demographics, comorbidities and estab-
lished laboratory tests, RIFLE severity class was the single
significant predictor of sustained AKI. However, when
urinary NGAL was added to RIFLE severity class in a
biomarker-assisted model, it independently added to the
predictive performance of the model (Po0.001). In addition,
three measures of the overall performance of the regression
model (R square, AUC-ROC, and diagnostic accuracy)
increased when NGAL was added to the model (Supplemen-
tary Table 1 online). These data indicate that RIFLE severity
Table 3 | Test characteristics of biomarkers in the prediction of intrinsic AKI versus prerenal AKI at different cutoff levels
Biomarker Cutoff level Sensitivity Specificity
Positive predictive
value
Negative predictive
value
Positive
likelihood ratio
Negative
likelihood ratio
Urinary NGAL (absolute level) 447 mg/l 0.89 (0.8–0.95) 0.53 (0.35–0.7) 0.82 (0.71–0.89) 0.68 (0.46–0.84) 1.91 (1.31–2.78) 0.2 (0.1–0.41)
4104 mg/l 0.75 (0.63–0.84) 0.88 (0.7–0.96) 0.93 (0.83–0.98) 0.6 (0.44–0.73) 5.97 (2.37–15.08) 0.29 (0.19–0.43)
Urinary NGAL (per urinary creatinine) 445 mg/g 0.88 (0.78–0.94) 0.55 (0.36–0.72) 0.82 (0.72–0.9) 0.65 (0.44–0.82) 1.94 (1.31–2.89) 0.22 (0.11–0.43)
4128 mg/g 0.72 (0.6–0.81) 0.87 (0.69–0.96) 0.93 (0.82–0.98) 0.56 (0.41–0.7) 5.55 (2.2–14.01) 0.33 (0.22–0.47)
Serum creatinine 4167 mmol/l 0.85 (0.75–0.92) 0.44 (0.27–0.62) 0.78 (0.67–0.86) 0.56 (0.35–0.75) 1.52 (1.1–2.09) 0.34 (0.18–0.63)
4205 mmol/l 0.63 (0.51–0.73) 0.66 (0.47–0.81) 0.81 (0.68–0.9) 0.43 (0.29–0.58) 1.82 (1.1–3.03) 0.57 (0.41–0.79)
RIFLE severity class (R=1, I=2, F=3) 2 0.88 (0.78–0.94) 0.34 (0.19–0.53) 0.76 (0.65–0.84) 0.55 (0.32–0.76) 1.34 (1.03–1.75) 0.35 (0.17–0.72)
3 0.49 (0.38–0.61) 0.88 (0.7–0.96) 0.9 (0.76–0.97) 0.42 (0.31–0.55) 3.95 (1.53–10.15) 0.58 (0.46–0.73)
Serum urea/serum creatinine ratio
(urea (mmol/l)/creatinine (mmol/l))
o63 0.45 (0.34–0.57) 0.89 (0.7–0.97) 0.92 (0.76–0.98) 0.38 (0.26–0.51) 4.07 (1.36–12.18) 0.62 (0.5–0.77)
o84 0.63 (0.51–0.74) 0.63 (0.42–0.8) 0.82 (0.69–0.91) 0.39 (0.25–0.54) 1.7 (1.01–2.87) 0.59 (0.42–0.83)
Abbreviations: AKI, acute kidney injury; NGAL, neutrophil gelatinase-associated lipocalin; RIFLE: Risk, Injury, Failure, Loss of function, End stage renal disease.
Optimal cutoff levels for NGAL (mg/l) were derived from an independent patient cohort in the emergency room.24 Cutoff levels of the remaining biomarkers represent
adjusted percentiles in the current study population to ensure comparability of the results.
Table 4 |Multiple logistic regression models for the prediction of an unfavorable clinical course (step-up in RIFLE severity class,
dialysis initiation, or mortality)a
Parameters Wald score P-value Odds ratiob R square AUC-ROCb Diagnostic accuracy
Biomarker model
Age (470 years) 3 0.083 0.5 (0.2–1.1) 0.215 0.74 (0.64–0.83) 74.50%
Serum creatinine (4205mmol/l) 4.6 0.031 2.3 (1.1–4.9)
Urinary NGAL (4104mg/l) 13.3 o0.001 4.2 (1.9–9.0)
Conventional model
Age (470 years) 3.3 0.068 0.5 (0.25–1.1) 0.093 0.65 (0.56–0.75) 68.30%
Serum creatinine (4205mmol/l) 6.3 0.012 2.5 (1.2–5.2)
Abbreviations: AKI, acute kidney injury; AUC-ROC, area under the receiver-operating characteristic curve; CKD, chronic kidney disease; NGAL, neutrophil gelatinase-associated
lipocalin; RIFLE: Risk, Injury, Failure, Loss of function, End stage renal disease.
aBoth models were adjusted for gender, histories of CKD, congestive heart failure, vascular disease, hypertension, diabetes, and RIFLE class.
bData in parentheses are 95% confidence intervals.
Wald score, P-value, and odds ratio are parameters to describe the contribution of the individual covariate to the model. R square, AUC-ROC, and diagnostic accuracy are
measures of the overall performance of the model.
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class and NGAL level are independent predictors of sustained
AKI. This further supports the notion that RIFLE class and
biomarker levels can be used in a complementary manner to
improve clinical risk prediction in established AKI.
DISCUSSION
In a patient cohort with established AKI as defined by RIFLE
criteria, urinary NGAL at the time of presentation distin-
guished intrinsic AKI from prerenal AKI and predicted an
unfavorable clinical course. ROC analyses indicated that
NGAL performed significantly better than conventional
laboratory tests in diagnosing intrinsic AKI. Logistic regres-
sion analysis indicated that NGAL was an independent
predictor of an unfavorable clinical course and markedly
improved the performance of the prediction model. In
addition, our study suggests that NGAL may help in
stratifying subclasses within the RIFLE severity classification,
in particular, within the RIFLE-I severity class.
Although urinary NGAL is well established as a biomarker
for the early diagnosis of AKI, our knowledge about its role in
established AKI is limited. Our study is the first to
systematically group patients with established AKI into
distinct diagnostic categories, namely prerenal and intrinsic
AKI, and link these categories with biomarker levels. To avoid
bias in the diagnostic adjudications, study physicians were
strictly blinded to the results of biomarker analyses and
followed predefined guidelines to assign patients to diag-
nostic categories. To ensure a high quality dataset, patients
with diagnostic ambivalence were excluded from the analysis.
Our analysis of test characteristics of NGAL excretion
indicated a good performance of NGAL in discriminating
intrinsic AKI and prerenal AKI according to ROC analyses
(AUC-ROC 0.87). NGAL performed significantly better in
diagnosing intrinsic AKI than serum creatinine, RIFLE class,
UC ratio, FeNa, and FeUrea. We also validated cutoffs derived
from an independent emergency room study.23 Analyses of
these cutoffs on our patient cohort confirmed that an NGAL
p47 mg/l made intrinsic AKI decidedly unlikely, whereas an
NGAL 4104 mg/l was indicative of intrinsic AKI. These data
are also consistent with a previous study carried out in
emergency room patients, which showed that NGAL
effectively discriminated patients with intrinsic AKI from
those with prerenal azotemia, stable CKD, and normal renal
function.20 Notably, urinary NGAL levels had similar test
characteristics whether or not they were corrected for urinary
creatinine concentrations.
We were surprised to note the poor performance of several
conventional indices used to differentiate intrinsic and
prerenal AKI. Most remarkably, FeNa did not significantly
discriminate prerenal and intrinsic AKI and FeUrea had only
marginal performance. The limited diagnostic utility of these
urinary indices had been previously acknowledged24 and, in
our cohort, may be explained in part by the high prevalence
of congestive heart failure (69.7%) and hypertension
(81.4%), as urinary indices are affected by diuretic therapy.
Our study confirmed the known association of AKI
etiology and outcomes. Although 33.8% of all patients and
50.7% of patients in the intrinsic AKI group experienced the
composite outcome indicating an unfavorable clinical course,
only 6.3% of patients with prerenal AKI experienced aspects
of the composite outcome. These data show that in our
cohort intrinsic AKI is an unfavorable predictor.
We further explored the utility of urinary NGAL in
predicting unfavorable clinical outcomes. Several studies have
linked high NGAL levels with clinical outcomes, including
hemodialysis initiation, progression of AKI, and mortal-
ity.20–22,25,26 We defined a composite outcome for our study,
consisting of a step-up in RIFLE severity class, dialysis
initiation, or mortality after inclusion. NGAL performed well
in predicting this outcome with an ROC of 0.71. This result is
similar to the diagnostic performance of NGAL in the
prediction of poor clinical outcomes in other cohorts.27
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Figure 4 | Sub-stratification of RIFLE severity classes by
neutrophil gelatinase-associated lipocalin (NGAL). Patients
were stratified by RIFLE severity class (R, I, F) and by NGAL level
(cutoff 104 mg/l). Percentages of in-hospital mortality, in-hospital
dialysis initiation, or a composite outcome are plotted by RIFLE
class and NGAL levels. *Po0.05 versus NGAL p104 mg/l. RIFLE:
Risk, Injury, Failure, Loss of function, End stage renal disease.
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Importantly, logistic regression analysis indicated that a
conventional prediction model that included age and serum
creatinine was markedly improved when urinary NGAL level
was added to the model. In a secondary endpoint analysis,
NGAL was also a major predictor of sustained AKI (RIFLE-
AKI lasting more than 3 days) and independently added to a
multiple regression model that also included the main
conventional predictor of sustained AKI, RIFLE severity
class. These results indicate that the addition of NGAL
significantly improves conventional prediction models of
unfavorable clinical courses even after AKI has been
established. This predictive utility of urinary NGAL may be
due—at least in part—to its ability to identify intrinsic
damage to the nephron.
One of the strengths of our study in comparison to earlier
studies is that urinary NGAL levels were determined on a
standardized clinical platform that is, or shortly will be,
widely available to clinicians. This state-of-affairs overcomes
one of the main limitations of earlier studies, which derived
their results based on experimental NGAL assays. However,
our study also has limitations. First, this study was carried
out in a single center. Second, the adjudicators assigned the
diagnostic categories intrinsic AKI versus prerenal AKI based
on the clinical information they had available. Thus, these
categories could not be based on gold standard measures
such as renal biopsy results, but instead relied on creatinine
dynamics and on the response to clinical intervention. This
resulted in a group of ‘unclassifiable’ patients. Inspection of
baseline criteria, outcomes, and biomarker levels indicates
that this unclassifiable group represents an intermediate
group of patients that displays neither ‘purely prerenal’ nor
‘purely intrinsic AKI’. We also attempted to conduct an
outcome analysis on unclassifiable patients only. However, we
did not find a significant association of urinary NGAL or
serum creatinine with composite or individual outcomes in
these patients, which is likely explained by insufficient
statistical power in this relatively small group (n¼ 38) with
only few clinical outcomes (n¼ 9). Finally, the conclusion
that patients of individual RIFLE severity classes can be sub-
stratified using urinary NGAL is based on a post hoc analysis
of our data set and clearly requires confirmation by
additional studies. Nonetheless, our study clearly indicates
a value of urinary NGAL in established AKI beyond that of
currently used laboratory tests.
MATERIALS AND METHODS
Patient population
The Charite´ University Ethics Committee approved the study (EA3/
011/08) and written informed consent was obtained. All hospitalized
patients meeting the RIFLE classification (either a450% increase in
serum creatinine concentration or a 425% decrease in glomerular
filtration rate compared with baseline)3 were eligible for assessment
and were generally enrolled at the time of nephrology consultation.
Two study physicians collected urine and blood samples, and
obtained a clinical follow-up from the medical records. The study
physicians were not involved in managing the patients. Patients were
initially included (n¼ 161) when the study physician confirmed
AKI. Patients were excluded from the study when an assignment of
the baseline creatinine level was not possible, when sufficient follow-
up was not available, or when postrenal obstruction was identified as
a cause of AKI (n¼ 16).
Sampling and measurement of renal biomarkers
We obtained initial urine and blood samples and a follow-up urine
sample 2 days after enrollment. We centrifuged urine samples at
3000 r.p.m. for 10 min and stored the supernatants at 80 1C.
Urinary NGAL was measured using ARCHITECT (Abbott Labora-
tories, Abbott Park, IL) technology, which uses a non-competitive,
two anti-analyte antibody sandwich.28 In this assay, the first
antibody is covalently attached to paramagnetic microparticles
and the second antibody is covalently attached to acridinium. NGAL
measurement was performed using an automated sequence, wherein
urine sample and microparticle reagents were incubated together for
18 min, then particles were washed, and the acridinium labeled
antibody was added for 4 min. After a second wash, the acridinium
label was triggered by peroxide and base. The chemiluminescent
signal was calibrated using known quantities of recombinant NGAL.
The maximum NGAL concentration of standards was 1500 ng/ml
and specimens with greater concentrations were diluted to read
within the calibration range. Creatinine, sodium, urea, FeNa, and
FeUrea determinations were part of the routine clinical assessments
of AKI patients at our institution and were determined by standard
automated methods (Jaffe´ reaction for creatinine, ion selective
electrode for sodium, urease/glutamate-based kinetic test for urea).
Estimated glomerular filtration rate was calculated with the
Modification of Diet in Renal Disease formula.
Diagnosis and outcomes
Diagnostic adjudication was performed by two clinical consultants,
who were instructed to use all available data, including the
precipitating events, the time course of serum creatinine concentra-
tion, the response to treatment including volume resuscitation,
modification of diuretic dosage, the use of vasopressors, immuno-
suppressive drugs, and the result of renal biopsies when available.
Consultants were blinded to NGAL levels, but not to other
laboratory tests. Baseline serum creatinine was determined by
review of the previous 12 months of the medical record, or if
unavailable, baseline serum creatinine was assumed from the
hospital course. The most likely causes for the increase in creatinine
were recorded and patients were classified into the three categories:
prerenal AKI, intrinsic AKI, or unclassifiable.
By the inclusion criterion, all patients displayed RIFLE-AKI on
the day of enrollment. Patients were classified as ‘prerenal AKI’,
when the increase in serum creatinine concentration had been
caused by factors that compromise renal perfusion, and when
creatinine rapidly improved to baseline with volume repletion or
improvement in cardiac output within 3 days of directed therapy. In
select cases (n¼ 6), patients with a slower normalization of serum
creatinine (within 7 days) were scored as prerenal, when the slow
course was clearly due to the fact that a more careful hydration
regimen was warranted (for example, in congestive heart failure). In
patients with prerenal AKI, there had to be no pre-enrollment
exposure to insults that result in intrinsic kidney damage (for
example, nephrotoxin exposure).
Patients were classified as ‘intrinsic AKI’ when the increase in
serum creatinine concentration had been caused by a potential acute
tubular necrosis-inducing event, such as prolonged hypotension,
sepsis, systemic inflammatory response syndrome, or other insults
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associated with structural damage to the kidney. The latter included
glomerulonephritis, vasculitis, preeclampsia, interstitial nephritis,
contrast nephropathy, multiple myeloma, and thrombotic micro-
angiopathy. In patients with intrinsic AKI, serum creatinine levels
did not respond appropriately to fluid resuscitation and/or
hemodynamic optimization.
When disagreements between the two clinical consultants
occurred, they convened to discuss the case. If that resolved the
disagreement, the diagnosis was revised according to the outcome
of the discussion. However, when a level of disagreement or
uncertainty remained, the patient was placed into the ‘unclassifiable’
category. These cases also included patients that were exposed to
additional clinical events after inclusion that may have affected the
serum creatinine time course. Additional ambiguous cases occurred
when a potential nephron-damaging event had preceded the onset
of RIFLE-AKI, but when creatinine normalized quickly or when the
timing of recovery was not clearly discriminatory between prerenal
AKI and intrinsic AKI.
The prospective composite outcome of the study was an
unfavorable clinical course defined by a step-up in RIFLE severity
class (RIFLE-R to RIFLE-I or RIFLE-I to RIFLE-F) within 7 days
from the time of inclusion, need for in-hospital renal replacement
therapy, or in-hospital mortality. The secondary outcome of the
study was ‘sustained AKI’ defined as RIFLE-AKI that lasted for more
than 3 days.
NGAL cutoff levels
Urinary NGAL cutoff levels analyzed in this study were derived from
the study on an independent multicentric cohort of 1677 patients
admitted to emergency departments in the United States and in
Germany.23 In that study, we had tested whether urinary NGAL
levels effectively discriminated patients with intrinsic AKI from
those with prerenal AKI, CKD or normal kidney function. We had
found that urinary NGAL levels below 47 mg/l (corresponding to the
60th percentile of urinary NGAL levels across the entire cohort)
made a diagnosis of intrinsic AKI unlikely, whereas urinary NGAL
levels higher than 104mg/l (corresponding to the 75th percentile of
urinary NGAL levels across the entire cohort) were indicative of
intrinsic AKI.23 To validate these cutoffs in an independent cohort,
we analyzed test characteristics of these NGAL cutoffs in the current
study population. Cutoff levels of the remaining tests (serum
creatinine, RIFLE severity class, UC ratio) represent percentiles
within the current cohort that correspond to these NGAL cutoffs to
ensure comparability among different tests.
Statistical analysis
For statistical analyses, we used PASW Statistics Version 18.0 or 19.0
(SPSS, Chicago, Illinois) and SAS, version 9.1 (SAS Institute, Cary,
North Carolina). We compared continuous variables between two
groups using Student’s t-test and categorical variables by using
w2 tests, rejecting the null hypothesis at Po0.05. Data are presented
as mean (s.d.) or median (interquartile range). We determined ROC
curves and calculated area under the curve including 95%
confidence intervals. We compared areas under the ROC curves
using nonparametric tests.29 We calculated sensitivity, specificity,
positive predictive value, and negative predictive value, positive
likelihood ratio and negative likelihood ratio including 95%
confidence intervals using efficient-score method (corrected for
continuity).30 To determine the association of biomarkers (NGAL,
FeNa, FeUrea, serum creatinine, and UC ratio), demographic
variables (age 470 years, gender, race), comorbid conditions
(diabetes, hypertension, congestive heart failure, coronary artery
disease, peripheral artery disease, cerebrovascular disease, preexist-
ing CKD), and RIFLE severity class (1¼R, 2¼ I, 3¼ F), with the
composite outcome of unfavorable clinical course or with the
secondary outcome of sustained AKI, we used univariate logistic
regression analysis followed by multivariate logistic regression with
stepwise entry (forward) or exit (backward) of variables to minimize
the number of covariates in the model. We then constructed final
models based on variables that remained associated with the prediction
of the composite outcome (age470 years, creatinine4205mmol/l, and
NGAL 4104mg/l) and with the prediction of sustained AKI (RIFLE
severity class, NGAL4104mg/l). The overall fit of the logistic regression
models was tested using Hosmer and Lemeshow test.
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